APRE

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that target DNA damage response pathways. Headquartered in Boston, Massachusetts, the company specializes in precision oncology treatments, particularly for hematologic malignancies and solid tumors with specific genetic mutations. Aprea's lead product candidate, eprenetapopt (APR-246), is a first-in-class small molecule designed to reactivate mutant p53 tumor suppressor protein, which is mutated in approximately half of all human cancers. The company advances this compound through various clinical trials targeting acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and other p53-mutated cancers. In November 2021, Aprea announced it would discontinue development of eprenetapopt following disappointing Phase 3 trial results in TP53-mutant MDS, representing a significant strategic setback. Subsequently, the company undertook a comprehensive business review and workforce reduction. In June 2023, Aprea completed a merger with Cyteir Therapeutics, shifting its focus to Cyteir's pipeline of synthetic lethality-based cancer therapies, including lead candidate CYT-0851, a RAD51 inhibitor. This transaction effectively transformed Aprea's business model and development pipeline, redirecting resources toward novel mechanisms in DNA damage repair for cancer treatment. The combined entity continues to trade under the APRE ticker symbol.